Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

PHASE2SuspendedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 11, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

October 31, 2024

Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
DRUG

Patients will be randomized to receive EHP-101 or Placebo

EHP-101 or placebo will be taken once a day

DRUG

Patients will be randomized to receive EHP-101 or Placebo

EHP-101 or placebo will be taken twice a day

Trial Locations (23)

2050

Royal Prince Alfred Hospital, Camperdown

2145

Westmead Hospital, Sydney

3011

Footscray Hospital, Footscray

5000

Royal Adelaide Hospital, Adelaide

6021

Wellington Hospital, Wellington

6150

Fiona Stanley Hospital, Murdoch

9726

Griffith University, Gold Coast

32701

Central Florida Pulmonary Group, Altamonte Springs

33063

Life Clinical Trials, Margate

33186

Novel Clinical Research Center, Miami

44195

Cleveland Clinic, Cleveland

55455

University of Minnesota, Minneapolis

60208

Northwestern University, Chicago

85032

Arizona Arthritis & Rheumatology Associates, P.C., Phoenix

90045

Pacific Arthritis Care Center, Los Angeles

90095

UCLA Division of Rheumatology, Los Angeles

91786

Inland Rheumatology Clinical Trials, Upland

92648

Care Access Research - Huntington, Huntington Beach

06511

Yale University, New Haven

08901

Rutgers, The State University of New Jersey, New Brunswick

00725

Centro Reumatologico, Caguas

00918

Mindful Medical Research, San Juan

00935

University of Puerto Rico, Medical Sciences Campus, San Juan

Sponsors
All Listed Sponsors
lead

Emerald Health Pharmaceuticals

INDUSTRY